| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Product Type | |
| Reporter | |
| Selection Marker | Puromycin, Blasticidin, N/A |
| Shipping | |
| Species |
Background
BIK (BCL2 interacting killer) is a pro-apoptotic member of the BH3-only subgroup of the BCL-2 protein family. By engaging and neutralizing anti-apoptotic proteins such as BCL-2 and BCL-XL, BIK promotes the activation of the effector proteins BAX and BAK, leading to mitochondrial outer membrane permeabilization and intrinsic-pathway apoptosis. BIK localizes largely to the endoplasmic reticulum and contributes to cellular responses to stress and to the regulation of cell survival. Its expression is frequently reduced or silenced in several tumor types, which can blunt apoptotic signaling and support tumor cell survival. BIK is therefore studied as a tumor suppressor and as a potential modulator of treatment sensitivity in cancer research.
Product Description & Applications
The Human BIK shRNA Lentivirus delivers a validated short hairpin RNA targeting human BIK for stable, RNA interference-based silencing. The 19-20 bp shRNA is expressed from a U6 Pol III promoter within a third-generation, self-inactivating lentiviral backbone, with a constitutively expressed fluorescent reporter (GFP, GFP/Luc, RFP, RFP/Luc) and an antibiotic selection marker (Puromycin or Blasticidin) co-expressed for tracking and stable line generation. VSV-G pseudotyping enables broad cell tropism, including primary, suspension, and cryopreserved cells. Knockdown efficiency is confirmed to meet or exceed 70% using a fluorescence-based assay. Particles are ultra-purified and concentrated to high titer by PEG precipitation and sucrose gradient centrifugation. The product supports loss-of-function studies of BIK in apoptosis regulation, tumor suppression, and cancer cell biology.
About This Product
This validated shRNA lentivirus targeting BIK (NCBI Accession: NM_001197.5) delivers a 19–20 bp shRNA from a third-generation, self-inactivating lentiviral backbone. Expression is driven from a U6 Pol III promoter, with a constitutively expressed fluorescent reporter (GFP, GFP/Luc, RFP, RFP/Luc) and antibiotic selection marker (Puromycin, Blasticidin) co-expressed from the same vector. VSV-G pseudotyping enables broad cell tropism, including primary, suspension, and cryopreserved cell types.
Knockdown is validated using a proprietary bicistronic fluorescence assay in which the target mRNA is co-expressed fused to RFP alongside the shRNA-GFP construct. At least 70% reduction in RFP signal in GFP-positive cells confirms on-target activity — a more direct functional readout than transcript-level qPCR. Polyclonal stable lines can be generated by antibiotic selection within 10 days, preserving parental cell heterogeneity compared to single-clone CRISPR approaches.
Can't find the lentiviral construct you need, or want to adjust key design elements? Contact us to discuss custom LV design and optional add-ons.
Common customization requests
- Insert / payload: replace the gene/sequence, swap to a different isoform, add mutations, or optimize cloning features.
- Expression design: change promoter (e.g., CMV/EF1α/PGK), add enhancers, or adjust regulatory elements.
- Reporters: add/swap GFP/RFP/mCherry/luciferase (single or dual reporters where applicable).
- Selection markers: add/swap puromycin/blasticidin/neomycin or fluorescent selection options.
- Vector format: switch between OE, shRNA, CRISPR (sgRNA/Cas systems), or control vectors (where supported).
Add-ons you can request
- Control viruses: empty vector, non-targeting shRNA, reporter-only controls, or matched backbone controls.
- Packaging / format: concentration options, aliquoting, or custom fill volume for screening workflows.
- Documentation: construct map/sequence confirmation package (as available) and batch documentation.
What to include in your request
- Target cell type/model (cell line or primary cells) and intended readout (reporter, knockdown, OE, etc.)
- Insert sequence (FASTA) or reference ID, plus any required tags/mutations
- Promoter, reporter, and selection marker preferences
- Desired scale and preferred format (aliquots / concentration requests)
Email us at support@biohippo.com or use the Talk to a Scientist request form.
